Phase 3 Transverse Myelitis Trial, Recruiting NCT07420296 Sponsor: Tianjin Medical University General Hospital Condition: Transverse Myelitis
Back to Transverse Myelitis

Phase 3 Transverse Myelitis Trial, Recruiting

NCT07420296
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been officially diagnosed with a condition called AQP4-IgG-positive NMOSD (a disease affecting the spinal cord and optic nerves), confirmed using the 2015 diagnostic guidelines
  • A blood test has shown that you carry a specific antibody called anti-AQP4
  • Your symptoms started no more than 30 days before joining the trial
  • If you have eye (optic nerve) involvement: your vision in the affected eye is quite poor (20/200 or worse) at the time of screening; and if this is a repeat episode, your vision before this episode was reasonably good (20/60 or better)
  • If you have spinal cord involvement: your physical disability score (a standard scale doctors use to measure walking and movement ability) is 5.5 or higher at screening; and if this is a repeat episode, your score before this episode was 3.5 or lower (confirm with trial site)
  • You are able to understand the study and are willing to sign a consent form agreeing to take part

Who may not be able to join:

  • You have another condition affecting your muscles or nerves at the same time
  • You have a serious problem with your blood's ability to clot
  • You have a known allergy to plasma or to intravenous immunoglobulin (a treatment given through a drip)
  • You currently have an active hepatitis B, hepatitis C, or HIV infection, or are considered at high risk of syphilis or tuberculosis
  • You have an active infection anywhere in your body right now, or you have a history of severe infections that keep coming back
  • You are currently pregnant or breastfeeding
  • You have a serious long-term health condition that might make it difficult for you to follow the study plan
  • Your blood test results show a significant abnormality, such as severe anaemia or very low white blood cell or platelet counts (confirm with trial site)
  • The trial doctor does not think you would be able to complete or follow the requirements of the study for any reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8602260814587

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Tianjin Medical University General Hospital
Registry
ClinicalTrials.gov
Start date
1 January 2026
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Best corrected visual acuity; Expanded Disability Status Scale (EDSS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov